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PATHOPHYSIOLOGY
Our understanding of the pathophysiology of graft-vs.-
host disease (GVHD) has improved greatly with re c e n t
insights into the cellular and humoral interactions that are
intrinsic to all inflammatory processes. In allogeneic bone
m a rrow transplantation (BMT), donor lymphocytes are
infused into a host that has been profoundly damaged. The
effects of underlying disease, prior infection, and condition-
ing regimen may result in substantial pro i n f l a m m a t o ry
changes in endothelial and epithelial cells. Donor cells
rapidly encounter an environment that not only is foreign,
but also has been altered to promote the activation and pro-
liferation of inflammatory cells by the increased expression
of adhesion molecules, cytokines, and cell surface re c o g n i-
tion molecules. The donor lymphocytes respond in turn by
reacting in a fashion that, under ord i n a ry circ u m s t a n c e s ,
would foster the control or resolution of infection. Thus,
the pathophysiology of acute GVHD may be considered as
a distortion of the cellular response to viral and gram-nega-
tive bacterial infection.
The principal target organs of GVHD also suggest a
close relationship between infection and GVHD. The skin,
gut, and liver all share an extensive exposure to endotoxins
and other bacterial products that can trigger and amplify
local inflammation. This exposure distinguishes them fro m
o rgans like the heart and kidneys that are not GVHD tar-
gets. The lung is an organ of controversy in this re g a rd .
While the lungs are not classic GVHD targets, accumulating
evidence suggests that they share some degree of GVHD
susceptibility with the skin, gut, and liver [1,2]. Because of
their situation as primary barriers to infection, these targ e t
o rgans have large populations of professional antigen-pre-
senting cells (APCs), such as macrophages and dendritic
cells, that may enhance the graft-vs.-host (GVH) re a c t i o n .
Recent findings implicate the excessive production of
cytokines, the central re g u l a t o ry molecules of the immune
system, as well as cellular effectors in the induction and
maintenance of experimental and clinical GVHD [3–5]. The
pathophysiology of acute GVHD can be considered in a
framework of three sequential phases [3,5].
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ABSTRACT
Graft-vs.-host disease (GVHD) remains the major toxicity of allogeneic bone marrow transplantation. Mechanistic
studies in experimental animal models provide a better understanding of the complex relationships and cascade of
events mediated by cellular and infla m m a t o ry factors. Also, advances in basic immunology have cleared the way for a
m o re precise view of allogeneic reactions between donor and host. In addition, the use of mutant mice lacking criti-
cal cytolytic proteins has helped map out the molecular pathways by which GVHD targets organ damage. In this
a rticle, these mechanisms are reviewed and synthesized into a coherent conceptual framework, providing a state-of-
t h e - a rt summary of the pathophysiology of acute GVHD.
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PHASE 1
Conditioning r e g i m e n
The earliest phase of acute GVHD starts before donor
cells are infused (Fig. 1). The transplant c o n d i t i o n i n g
re g imen is an important variable in the pathogenesis of acute
GVHD because it can damage and activate host tissues,
including the intestinal mucosa, liver, and other tissues. Acti-
vated host cells secrete infla m m a t o ry cytokines, such as tumor
n e c rosis factor (TNF)-a and interleukin (IL)-1 [6], and
g rowth factors such as granulocyte-machrophage colony-
stimulating factor (GM-CSF) [7–9]. The presence of infla m-
m a t o ry cytokines during this phase may upregulate adhesion
molecules [10] and major histocompatibility complex (MHC)
antigens [11–15], thereby enhancing the recognition of host
MHC or minor histocompatibility antigens by mature donor
T cells after the cellular component of the graft is infused.
This scenario is in accordance with the observation that an
enhanced risk of GVHD after clinical BMT is associated with
intensive conditioning regimens that cause extensive injury to
epithelial and endothelial surfaces with a subsequent re l e a s e
of infla m m a t o ry cytokines and increases in expression of cell
s u rface adhesion molecules [16–18]. The re l a t i o n s h i p
between conditioning intensity, infla m m a t o ry cytokines, and
GVHD severity has been further supported in animal models
[19]. More o v e r, the risk of inducing severe acute GVHD
appears to be less if the lymphocytes are infused well after the
p r i m a ry tissue injury has resolved [20,21].
PHASE 2
Donor T-cell activation
The second phase of acute GVHD includes antigen pre-
sentation, the activation of individual donor T cells, and the
subsequent proliferation and diff e rentiation of these activated
T cells. When a CD41 cell enters the recipient blood stre a m ,
it interacts with the MHC class II molecules of the APCs,
w h e reas a CD81 cell interacts with MHC class I antigens.
Several lines of evidence suggest that host APCs are part i c u-
larly important in GVH reactions, and eliminating host APCs
of hematopoietic origin can promote tolerance and re d u c e
GVHD [22,23]. When donor and recipient are not MHC
identical, donor T cells can recognize host MHC molecules
as foreign, and the resultant GVH reaction can be dramatic,
even against single MHC antigen diff e rences. In such cases,
“ n o n p rofessional APCs” that express MHC antigens may be
t a rgeted, depending on the expression of other costimulatory
molecules (see below). When the recipient and donor are
MHC identical, GVHD occurs through recognition by the
T cell and its receptor (TCR) of diff e rent peptides, so-called
minor histocompatibility (miH) antigens, bound to the same
MHC. Because the manner of protein processing depends on
genes outside of the MHC, two siblings will have many dif-
f e rent peptides in the MHC groove. There f o re, one potential
a rea to interf e re with signal recognition is at the level of
MHC-peptide-TCR interaction [24,25].
It is clear that GVHD after BMT from an MHC-identi-
cal sibling depends on the recognition of diff e rent allelic
peptide products presented by the same (i.e., shared) MHC.
The identification of these potential peptides has been an
a rea of intense re s e a rch. It remains unclear how many of
these peptides behave as miH antigens, although the esti-
mates from mouse studies suggest that 50 such antigens may
exist. The precise number of these antigens in humans is not
clearly defined. While there are many potential miH anti-
gens, the actual numbers that can potentially induce GVHD
(“major minors”) are likely to be limited and will probably
Figure 1. Acute GVHD pathophysiology
Pathologic mechanisms of GVHD as three sequential phases: I, recipient conditioning; II, donor T-cell activation, adhesion, costimulation, and cytokine production;
III, inflammatory and cytolytic effectors.
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prove less powerful stimulators of GVHD than MHC anti-
gens. Recent clinical data suggest that mismatches of miH
antigens between HLA-identical donors and recipients are
associated with GVHD [26]. Of five previously character-
ized miH antigens (HA-1, -2, -3, -4, and -5) recognized by
T cells in association with HLA-A1 and A2, mismatching of
HA-1 alone was significantly correlated with acute grade
II–IV GVHD (p 5 0.02), and mismatching at HA-1, -2, -4,
and -5 was also associated with GVHD (p 5 0.006). In all
cases where an HA-1–positive patient received an HA-
1–negative graft, acute GVHD developed; a mismatch at
HA-3 had no effect. Furt h e rm o re, peptide analysis of the
HA-2 antigen suggests that it is a member of the class I
myosin family [27].
The peptide itself can have profound consequences on
the outcome of the interactions of the TCR-peptide-MHC.
The recognition of slightly altered peptides can lead to par-
tial activation of T cells [28–30]. Peptides with minor varia-
tions of sequence compared to native peptide may lead to
significant changes in the T-cell response. There f o re the
TCR should not be thought of as a simple on/off switch but
rather as a rheostat, where subtle variations of peptide con-
figuration might have helpful or deleterious effects on the
ensuing immune response. Small changes in peptides may
shift a vigorous proliferative response to the induction of an
a n e rgic state (or vice versa). These variations in peptides
have been referred to as altered peptide ligands.
T-cell adhesion and costim u l a t i o n
When a mature T cell is suddenly placed into the circu-
lation of an allogeneic host, it will travel through the blood-
stream in a fashion similar to its journey in the donor. The
systemic vasculature, including the capillary beds, represents
the potential first and extensive area of contact with new
alloantigens for this T cell. Vascular antigens have therefore
been studied as potential miH antigens, and studies suggest
that they may be important in the pathogenesis of GVHD,
although the data are conflicting [31–33]. The degree to
which donor T cells are  stimulated by host vascular
endothelium, which may act as a nonprofessional APC when
activated, is currently under investigation.
B e f o re antigen recognition and activation, a T cell
must adhere long enough to a surface to become activated.
The current view of this process is that a T cell rolls along
the endothelial surfaces with its TCR in contact with a
variety of diff e rent antigens. The on and off rates of bind-
ing of the TCR to the MHC molecules have been estimat-
ed, and the binding (Km) of TCR to antigen is re l a t i v e l y
weak, which raises the likelihood that the TCR will engage
with a large number of MHC molecules [34]. If the TCR
recognizes any particular antigen that results in activation of
the T cell, adhesion molecules then firmly anchor the T cell
and prevent any further rolling. Various integrins and
selectins are critically important to this process [35].
M o re o v e r, these anchors also provide the possibility of
e g ress for T cells from the circulation into lymph nodes,
spleen, reticuloendothelial tissues, and other target org a n s .
I n t e rf e rence with adhesion could potentially weaken the
interaction between the TCR and the MHC molecule,
leading to a lower binding affinity and perhaps a weaker
immune response. Altern a t i v e l y, monoclonal antibodies
that block the interaction of adhesion molecules with their
ligands may physically prevent the dimerization of the
TCR and MHC molecules and subsequent intracytoplas-
mic signaling. A polymer that binds to the MHC molecule
or the peptide modeled after the D1-CD4 domain could
also cause such interf e re n c e .
T-cell activation requires two signals. The first signal is
p rovided by the TCR-peptide-MHC interaction [36,37].
For donor T cells, this signal is the interaction between the
allo-peptide bound to the host or donor MHC (Fig. 2). The
second, or costimulatory signal, requires contact with APCs
[38,39]. The second signal determines the outcome of the
activation sequence, leading to complete activation, part i a l
activation, or a long-lasting state of antigen-specific unre-
sponsiveness, termed anerg y. Several ligands can pro v i d e
costimulation for resting T cells, antigen-primed T lympho-
cytes, and T-helper cell clones. The best-characterized cos-
timulatory molecules are the B7 antigens, which bind to two
T-cell surface receptors, CD28 and CTLA-4. In norm a l
animals, the outcome of T-cell activation depends on a sig-
nal from the TCR, a costimulatory signal from CD28, and
an inhibitory signal from CTLA-4. This process has been
elegantly demonstrated in mice deficient for either CD28 or
CTLA-4 [40,41]. Signaling through the TCR complex in
the absence of costimulation results in a deactivation signal
that leads to anergy. Conversely, absence of CTLA-4 results
in loss of the inhibitory signal, resulting in enhanced and
uncontrolled cytokine production and proliferation. The use
Figure 2. Donor T-cell interactions with host APC
Molecular diagram of a CD41 donor T cell recognizing foreign protein anti-
gen via the T-cell receptor in the context of MHC II molecules.
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of CTLA-4 inhibition to induce donor T-cell anergy is cur-
rently being tested in a clinical phase I trial [42]. 
Costimulatory requirements for T cells depend on their
state of activation-induced maturation. For resting (unprimed)
C D 41 T cells, VCAM-1 and intercellular activation mole-
cule-1 (ICAM-1) (and possibly other molecules) have been
demonstrated to provide the costimulatory signal or signals.
Consequently, T-cell activation in vivo is very complex and
depends on the state of activation of the T cell (resting vs.
activated, naive vs. mature) as well as the nature of the APC
(professional vs. nonprofessional, resting vs. activated).
Interactions of CD40 and its ligand (CD40L) are also
i m p o rtant costimulatory signals for T-cell activation.
Human endothelial cells express CD40, and the interaction
with CD40L on the T cell can induce endothelial cell acti-
vation [38,43,44]. This activation can lead to incre a s e d
e x p ression of ICAM-1 (or CD54), E-selection (CD62E),
and VCAM-1 on endothelial cells. These interactions sug-
gest a mechanism whereby activated CD41 T cells may
increase their own response by causing increased expression
of endothelial cell surface adhesion molecules.
T-cell cytokines
T cells that secrete IL-2 and interferon (IFN)-g (type 1
cytokines) are critical mediators of acute GVHD. The
importance of GVHD has been demonstrated both experi-
mentally and clinically. First, IL-2 is secreted by donor
CD41 T cells in the first days after experimental allogeneic
BMT [45]. Second, the blockade of IL-2 with antibodies to
IL-2 or its receptor can inhibit the development of experi-
mental disease [45]. Clinically, the precursor frequency of
h o s t - s p e c i fic, IL-2–producing T cells (precursor fre q u e n c y
of helper T cells) is predictive for the risk of acute GVHD
[46,47]. In addition, soluble IL-2 receptor levels may be a
sensitive indicator of impending GVHD onset, and they
correlate with disease severity [48].
I n c reased serum levels of IFN-g a re associated with
acute GVHD, and lymphocytes from animals with GVHD
s e c rete significantly greater amounts of IFN-g than lympho-
cytes from controls without GVHD [49–53]. Additional evi-
dence of a role for IFN-g in experimental acute GVHD
includes priming of macrophages by IFN-g during acute
GVHD to produce infla m m a t o ry cytokines [54], induction
of pathology in skin tissues and the gastrointestinal tract by
I F N -g [55,56], suppression of T-lymphocyte function char-
acteristic of acute GVHD by IFN-g [57,58], prevention of
acute GVHD when CD81 cells are incapable of IFN-g p ro-
duction [59], and inhibition of acute GVHD by direct or
i n d i rect blockade of IFN-g [ 5 5 , 6 0 – 6 2 ] .
The preincubation of donor T cells in the presence of
the Th2 cytokine, IL-4, can polarize these T cells toward a
Th2 cytokine phenotype [61]. Transplantation of polarized
Th2 T-cell populations failed to induce acute GVHD to
MHC class I or class II antigens. These experiments strong-
ly support the concept that the balance in Th1 and Th2
cytokines is critical for the development (or prevention) of
acute GVHD. Further data show that Th2 cells maintain
some antileukemic efficacy and can support lymphohe-
matopoietic engraftment [62,63]. Data from experimental
BMT systems suggest that the use of G-CSF to mobilize
peripheral blood hematopoietic cells can lead to Th1→Th2
polarization of T cells in the stem cell innoculum, albeit
i n d i re c t l y, resulting in less GVHD than in saline-tre a t e d
controls [64–66]. This effect also changes the production of
other inflammatory cytokines such as TNF-a [67,68]. 
R e g u l a t o ry cells may also help determine the ultimate
response of donor T cells to host antigens. Double-negative
T cells (usually NK1.11) can suppress a T-cell response in a
mixed lymphocyte reaction (MLR) and can prevent GVHD
in vivo [69]. Pre s u m a b l y, these re g u l a t o ry cells develop to
c o n t rol the intensity of the overall response to a specific anti-
gen. The balance between reactive T cells and suppre s s o r
T cells could thus control the intensity of GVHD. The gen-
eration and maintenance of these suppressor cells are poorly
understood, although some effects may be related to diff e r-
ences in their cytokine milieu. Other potential avenues for
tolerance induction may occur at the cellular level. Groux e t
a l . [70] demonstrated that CD41 T cells, grown ex vivo in the
p rolonged presence of IL-10, suppressed infla m m a t o ry bowel
disease that was induced by pathogenic T cells. These cells
w e re termed “Tr1.” More o v e r, Tr1 cells have been isolated
f rom the peripheral blood of severe combined immunodefi-
cient patients after allogeneic stem cell transplantation, in
which high levels of IL-10 in vivo a re associated with
donor/host tolerance [71]. These results suggest that pro-
longed exposure of naive CD41 T cells to IL-10 may result in
a population of Tr1 cells that can regulate immune re s p o n s e s
and modulate GVHD.
PHASE 3
I n f l a m m a t o r y eff e c t o r s
The third phase of acute GVHD is complex and has only
recently been appreciated. The initial hypothesis that the
cytolytic function of cytotoxic T lymphocytes (CTLs) dire c t-
ly causes the majority of tissue damage in GVHD targets is
too limited [72]. Large granular lymphocytes (LGLs) or nat-
ural killer (NK) cells appear to be prominent in the eff e c t o r
a rm of GVHD in several animal models, and they may con-
tribute to the pathologic damage, i.e., induce the changes of
GVHD following the T-cell–mediated GVH re a c t i o n
[72,73]. LGLs do not recognize HLA proteins as targets, but
they can be re c ruited by cytokines released by T cells. 
Mononuclear phagocytes, which have been primed with
Th1 cytokines during phase 2, have an important role in this
phase of acute GVHD. Monocytes receive a second, trigger-
ing signal to secrete the infla m m a t o ry cytokines TNF-a a n d
IL-1. This stimulus may be provided by lipopolysaccharide
(LPS) (endotoxin), which can leak through the intestinal
mucosa damaged by the conditioning regimen and subse-
quently stimulate gut-associated lymphocytes and macro-
phages [54]. LPS reaching skin tissues may also stimulate
keratinocytes, dermal fib roblasts, and macrophages to pro-
duce similar cytokines in the dermis and epidermis [7–9].
Recent experimental data suggest that TNFL production by
donor cells in response to LPS is an important risk factor for
GVHD severity independent of T-cell responses to host
antigens [74]. TNF-a can cause direct tissue damage by
inducing necrosis of target cells, or it may induce tissue
d e s t ruction during GVHD through apoptosis (pro g r a m m e d
cell death). The induction of apoptosis commonly occurs
after activation of the TNF-a–Fas antigen pathway [75].
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Apoptosis is probably critical to GVHD in the large intestine
[76] and skin [77,78] and possibly in endothelial cells [79]. In
addition to these pro i n f l a m m a t o ry cytokines, excess nitric
oxide (NO) produced by activated macrophages may con-
tribute to the deleterious effects on GVHD target tissues,
p a rticularly immunosuppression [58,80,81]. Thus, the induc-
tion of infla m m a t o ry cytokines may synergize with the cellu-
lar damage caused by CTLs and NK cells [72,82], re s u l t i n g
in the amplification of local tissue injury and further pro m o-
tion of an infla m m a t o ry response, which ultimately lead to
the observed target tissue destruction in the BMT host.
The role of infla m m a t o ry cytokines in GVHD explains a
number of unique and seemingly unrelated aspects of
GVHD. For example, a number of analyses of clinical trans-
plants noted increased risks of GVHD associated with
advanced-stage leukemia, certain intensive conditioning re g i-
mens, and viral infections [16–18]. Similarly, the reduction in
GVHD seen in gnotobiotic mice [83,84] and patients with
aplastic anemia undergoing transplantation in laminar airflo w
e n v i ronments with gut decontamination [85] may be
explained by the reduction of bacterial LPS on the skin and
gut. LPS may leak through damaged intestinal mucosal sur-
faces and stimulate the numerous gut-associated lymphocytes
and macrophages to produce infla m m a t o ry cytokines. The
beneficial effect of protective environments may be less
a p p a rent in patients receiving transplants for malignancies,
because prior therapy and associated infections may have
resulted in an environment that facilitates GVHD. Vi r a l
infections are also commonly associated with GVHD. They
a re more frequent in patients with GVHD, and a viral illness
may cause the initiation of GVHD or worsening of estab-
lished GVHD. Cytomegalovirus has a particularly close re l a-
tionship with GVHD [86–89], as does herpes simplex viru s
[90–92], and possibly human herpes virus-6 [93]. The pre c i s e
pathophysiology of this connection remains uncertain. While
it has been hypothesized that viral antigen expression on tar-
get cells might function as a minor histocompatibility anti-
gen, direct evidence proving this association is lacking. Cer-
t a i n l y, cellular damage to the intestine or liver may incre a s e
the permeability of those organs, resulting in incre a s e d
absorption of bacterial products such as LPS. Altern a t i v e l y,
GVHD targets could be innocent bystanders of either a
v i rus-induced activated T-cell or an NK-cell attack [94,95]. 
C y t o l ytic eff e c t o r s
Although cytokines clearly play important roles in the
morbidity and mortality of systemic GVHD, they may be
less important as mediators of damage in individual GVHD
target organs. The unusual cluster of GVHD target organs
(skin, gut, and liver) is not adequately explained by the sys-
temic release of cytokines. For example, intravenous infu-
sion of TNF-a and IL-1 does not cause the lymphomononu-
clear cell infiltration of liver and skin observed in GVHD.
F u rt h e rm o re, the absence of GVHD toxicity in other vis-
ceral organs, such as the kidneys, argues against circulating
cytokines as the sole causation of tissue-specific damage. 
Since cytotoxic T cells possess the capacity to kill vir-
tually all nucleated cells, cell-mediated cytotoxicity is
thought to contribute to the destruction of GVHD targ e t
tissues. T cells can effect cytolysis by either direct contact
or the release of soluble mediators such as TNF-a. Con-
tact-dependent cell-mediated cytotoxicity can occur
t h rough a secre t o ry pathway involving granule release or
by effector cell membrane ligand interaction with death
receptors on the membrane of the target cell [96,97] (Fig. 3 ) .
After secretion of granules by the effector cell, the poly-
merization of perforin on binding to the target membrane
is crucial to optimize penetration of granule cont e n t s ,
Figure 3. CTL effector pathways
The various components of the molecular pathways of CTL-mediated lysis. Fas, CD95/AP01; DR3, AP03/WSL1/TRAMP/LARD; DR4, TRAIL R1; DR5,
TRAIL R2/TRICK 2, KILLER-DR5; TRAIL, AP02L.
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including granzymes A and B, into the targeted cells.
H o w e v e r, evidence suggests that perforin and granzymes
may also gain access to the target cell cytosol by other
means [98–100]. Apoptosis of target cells is then rapidly
induced by granzyme B activation of the caspase cascade.
This cascade ultimately results in the release of an
inhibitor (ICAD) bound to a caspase-associated DNase
molecule (CAD), which is followed by fragmentation of
t a rget cell DNA. A common pathway appears to operate in
signaling through the Fas-associated death domain
( FADD) of the so-called death receptors (DR). A number
of ligands have been identified on T cells that possess the
capability to trimerize TNFR-like DR molecules. In addi-
tion to the well-characterized FasL (CD95L)-Fas (CD95)
DR ligand-receptor pair, additional molecules including
TWEAK (DR3 ligand) and TRAIL (DR4,5 ligand) have
recently been identified as capable of activating the caspase
system and subsequent apoptosis [101–104] (Fig. 3).
Although the physiologic functions of DR3, 4, and 5 are
not presently known, the expression of TRAIL and
TWEAK on T cells may be important contributors during
transplant responses to this pro c e s s .
During the past several years, a number of experimental
allogeneic BMT studies have used donor grafts that are
unable to mediate either perforin/granzyme or FasL-Fas
dependent killing [105–110]. Transplantation of perf o r i n -
deficient T cells results in a marked delay in the onset of
GVHD-associated weight loss and mortality in both MHC
and miH incompatible systems [105,106]. However, these
studies also revealed that although greater numbers of per-
forin-deficient T cells were required to induce GVHD with
kinetics comparable to that caused by normal T cells, weight
loss and mortality were, in fact, induced in the absence of
p e rforin-dependent killing. More o v e r, the clinical signs of
GVHD, including kyphosis, alopecia, skin lesions, and diar-
rhea, as well as histopathologic changes in the skin, liver,
and lymphohematopoietic compartment, were all eventually
observed [105,106].
Studies employing donor T-cell subsets show that
granzyme B–deficient CD81 T cells induced significantly less
m o rtality than wild-type T cells in experimental transplants
a c ross a single MHC I mismatch or complete MHC I and II
mismatches [107,110,111]. Titration of donor T cells demon-
strated a three- to fivefold diff e rence in the number of per-
forin/granzyme B–deficient CD81 T cells re q u i red to medi-
ate comparable GVHD, but titration of perf o r i n / g r a n z y m e
B–deficient CD41 T cells produced conflicting re s u l t s
[107,110,111], and thus the contribution of this pathway to
GVHD induced by CD41 T cells is less cert a i n .
Although the perforin/granzyme pathway may contribute
to tissue injury, it is now clear that it is not necessary to gen-
erate tissue damage. Because increased numbers of perf o r i n
d e ficient cells can induce comparable weight loss and mort a l i-
ty with the same kinetics as normal donor cells, the killing of
host cells via perforin may be a contributor to the “aff e re n t ”
events (phases 1 and 2) of acute GVHD. Studies have shown
that macrophages and dendritic cells (APC populations) can
be killed by both perforin- and FasL-dependent pathways
[112–114]. The amplification/expansion of donor T cells may
be facilitated by efficient lysis of host cells and the subsequent
release of host alloantigens and cytokines from host APCs.
Early during GVHD, perforin/granzyme function directed at
host cells may also protect alloreactive donor T cells by elimi-
nating host T/NK-populations that can regulate or impede
donor T cells [115].
Perforin-deficient T cells retain the capacity to mediate
FasL-dependent killing. Accordingly, experiments have been
p e rf o rmed to examine the consequences of transplanting
donor cells unable to cause Fas-mediated apoptosis. These
studies have used T cells from mice with a naturally occur-
ring genetic mutation (g l d / g l d) resulting in a FasL pro t e i n
that cannot trimerize Fas and there f o re fails to induce Fas
signaling [116]. Transplantation of donor T cells with func-
tionally defective FasL in CD81-dependent models resulted
in only modest delay in weight loss and in a small increase in
median survival time (MST) [106,109]. However, the ability
to induce acute GVHD by FasL-defective donor cells was
significantly impaired in CD41-dependent models
[107,109,110]. These studies suggest that FasL is more
i m p o rtant for GVHD induced by CD41 T cells where a s
p e rforin/granzyme is more important for GVHD depen-
dent on CD81 T cells [106–110].
These murine models also suggest that perforin and
FasL pathways are not equally important for all targ e t
o rgans. For example, FasL-mediated cytotoxicity is an
i m p o rtant effector pathway in hepatic GVHD, even in
C D 81 T-cell–dependent models [106]. A number of non-
GVHD studies have reported that the liver appears particu-
larly sensitive to Fas-induced injury [117–120]. Consistent
with these findings, a recent study observed that transplan-
tation of MiH-disparate allogeneic T cells failed to induce
hepatic GVHD in Fas-deficient recipients (M. Van den
Brink, personal communication). Another recent study
re p o rted that administration of anti-FasL (but not anti-
TNF antibody) significantly blocked the hepatic damage
occurring in an MHC nonidentical GVHD model [121].
Cutaneous GVHD may also be mediated by FasL cyto-
t o x i c i t y, even in CD81 T-cell–dependent GVHD systems
[106]. Minimal inflammation was observed in skin sections
f rom recipients of miH-mismatched FasL-defective donor
T cells, suggesting that FasL-Fas was an effector pathway of
GVHD in the skin. Although constitutive Fas expression in
the skin is low, keratinocytes have been found to express Fas
during viral infections and certain cutaneous diseases [122].
Cytokines induced during GVHD may also upregulate Fas
expression in the skin, and several studies have demonstrat-
ed that anti-TNF-a antibody inhibited the development of
skin GVHD [78,123]. TNF-a and INF-g can upre g u l a t e
FasL expression on keratinocytes [124], and a recent investi-
gation found that the introduction of either anti-FasL or
anti-TNF antibody diminished GVHD skin lesions [121].
Injection of both antibodies completely prevented skin dam-
age, and thus signaling through both Fas and TNF recep-
tors may both contribute to GVHD-associated skin injury. 
In contrast to FasL involvement in hepatic and cuta-
neous GVHD, TNF-a plays a dominant role in intestinal
GVHD damage. Anti–TNF-a but not anti-Fas antibody
blocked gastrointestinal damage in MHC-mismatched
GVHD [121]. FasL may play a small role, however, because
one study re p o rted that intestinal intra-epithelial lympho-
cytes from a P→F1 GVHD model exhibited increased FasL-
mediated intestinal apoptosis after transfer to normal mice
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[125]. Additional studies are needed to further elucidate the
involvement of these molecules in intestinal GVHD. 
F i n a l l y, transplant of FasL-defective donor T cells has
also resulted in a diminution in the level of lymphoid
(splenocyte and thymocyte) depletion in recipients [106,
108,109]. Similar to results detected in the skin, treatment
with either anti-FasL or anti–TNF-a antibody re d u c e d
lymphoid depletion [121].
The use of a perforin/granzyme and FasL cytotoxic
double-deficient (cdd) inoculum provides the opportunity to
a d d ress whether other effector pathways are capable of
inducing GVHD target organ pathology. Braun et al. [126]
re p o rted that perforin/FasL-defective donor spleen cells
were unable to induce GVHD lethality in recipients trans-
planted after 6.5 cGy TBI with cells from MHC I/II–mis-
matched donors. However, resistance by the host after non-
lethal TBI may have significantly diminished the GVHD
capacity of the donor inoculum. Two subsequent studies
transplanted cdd donor cells into MHC-mismatched recipi-
ents conditioned with lethal TBI and observed significant
GVHD [127,128]. T cells concomitantly unable to mediate
both perforin/granzyme- and FasL-dependent cytotoxicity
w e re capable of inducing GVHD, although considerably
greater numbers of cdd cells were required. A recent study
employing granzyme B- and FasL-deficient T-cell subsets
suggests that such CD81 T cells cannot induce GVHD
[110], whereas CD41 T cells unable to mediate perf o r i n -
and FasL-dependent cytotoxicity can (Z. Jiang, R. Levy,
unpublished observations). These results demonstrate that
other effector molecules can cause severe GVHD in the
absence of perforin/granzyme and FasL. Future studies will
undoubtedly focus on the newly emerging death re c e p t o r
ligands, together with cytokines including TNF-a. 
In summary, recent investigations have begun to defin e
the contributions of cell-mediated cytotoxicity via both per-
forin/granzyme- and FasL-dependent pathways to both sys-
temic GVHD and to GVHD target organ damage. The
newly emerging molecular pathways of death signals should
p rovide more complete and precise definitions of re q u i re-
ments for GVHD-induced pathogenesis. Since both CD41
and CD81 cells mediate GVHD and graft-vs.-leukemia
(GVL) activity, assessing the relative contributions of each of
the cytotoxic pathways in individual subsets may help in the
potential disassociation of GVHD from GVL. As our under-
standing deepens of the relative contribution of each of these
pathways to GVHD pathology in individual GVHD targ e t
o rgans, novel strategies may emerge to optimize pro p h y l a x i s
and therapy for individual host tissues.
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